Both Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss. Ozempic contains semaglutide (GLP-1 agonist). Mounjaro contains tirzepatide (dual GIP/GLP-1 agonist). If your goal is weight management, the FDA-approved versions are Wegovy (semaglutide) and Zepbound (tirzepatide).
Why people compare Ozempic and Mounjaro
Ozempic and Mounjaro are the two most-prescribed GLP-1 medications for type 2 diabetes, and both have gained massive public attention for their weight loss effects. Search volume for both brand names dwarfs their FDA-approved weight loss counterparts, Wegovy and Zepbound.
The comparison is clinically relevant for diabetes management. But for patients whose primary goal is weight loss, comparing Ozempic and Mounjaro is comparing the wrong two medications. The right comparison is Wegovy vs. Zepbound.
The key difference: mechanism of action
Ozempic (semaglutide) activates GLP-1 receptors. This mimics a natural gut hormone that reduces appetite, slows gastric emptying, and improves insulin secretion. It targets one receptor system.
Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors. This dual-agonist approach amplifies the metabolic effects — greater appetite suppression, more potent insulin sensitization, and in clinical trials, more weight loss than single-agonist GLP-1 medications.
Mounjaro's dual GIP/GLP-1 mechanism produces more weight loss than Ozempic's GLP-1-only approach. But for weight loss, both have FDA-approved counterparts designed for that purpose.
Side-by-side comparison
| Feature | Ozempic | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA indication | Type 2 diabetes | Type 2 diabetes |
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Dose range | 0.25–2.0 mg | 2.5–15 mg |
| A1C reduction | ~1.5–1.8% (SUSTAIN trials) | ~2.0–2.4% (SURPASS trials) |
| Weight loss (secondary) | ~12–15 lbs (SUSTAIN) | ~15–25 lbs (SURPASS) |
| FDA approval | December 2017 | May 2022 |
| Weight loss version | Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide) |
| Common side effects | Nausea, diarrhea, vomiting | Nausea, diarrhea, decreased appetite |
| Controlled substance | No | No |
Weight loss figures represent secondary endpoints from diabetes trials with diabetes-specific dosing protocols, not weight-loss-optimized studies.
For weight loss patients: use the right medication
If you don't have type 2 diabetes but want to lose weight, Ozempic and Mounjaro are the wrong starting point. Both are FDA-approved exclusively for diabetes. Using them off-label for weight loss creates insurance headaches, dosing limitations, and ethical supply concerns.
- Wegovy — the FDA-approved weight loss formulation of semaglutide at a higher maximum dose (2.4 mg vs. 2.0 mg)
- Better insurance pathways for weight management
- FDA-approved cardiovascular benefit (MACE reduction via SELECT trial)
- Zepbound — the FDA-approved weight loss formulation of tirzepatide (identical molecule, same dose range)
- Weight-specific insurance coverage with PA
- Additional FDA indication for obstructive sleep apnea
- Single-dose vial option alongside pens
Mounjaro and Zepbound contain the exact same molecule (tirzepatide) at the exact same doses (2.5–15 mg). The only difference is FDA indication and billing code. Ozempic and Wegovy share the same molecule (semaglutide) but differ in maximum dose: Ozempic caps at 2.0 mg while Wegovy goes to 2.4 mg. This is why using the correct brand matters for weight loss patients.
When this comparison comes up
We hear this question most often from patients who were started on Mounjaro or Ozempic by their primary care doctor for type 2 diabetes and are now asking whether their medication also helps with weight. The short answer: both can cause weight loss as a side effect, but neither is FDA-approved for that purpose. If weight loss is your primary goal, the conversation shifts to Wegovy (semaglutide, like Ozempic) or Zepbound (tirzepatide, like Mounjaro) — both approved specifically for chronic weight management.
There is also an insurance dimension. Most commercial plans will not cover Ozempic or Mounjaro for weight loss because the FDA indication does not match. Filing a claim for off-label use can result in a denial, a delay, or a prior authorization loop that takes weeks. At PEAK, we prescribe the FDA-approved weight loss formulation from the start, which simplifies the insurance process and avoids coverage gaps down the line.
What PEAK prescribes for weight loss
PEAK does not prescribe Ozempic or Mounjaro for weight loss. Both are diabetes medications, and we believe in prescribing the right medication for the right indication. For weight management, we prescribe Wegovy and Zepbound.
If you're currently on Ozempic or Mounjaro for diabetes and also want to address weight, talk to your clinician about your overall treatment plan. If you don't have diabetes and are seeking weight management, we'll start with the medication designed for that purpose.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
